A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Etentamig
DRUG: Lenalidomide
DRUG: Daratumumab
DRUG: Dexamethasone
DRUG: Dexamethasone

Sponsor

AbbVie

Collaborators

IFM (Intergroupe Français du Myélome); PETHEMA (Program for the Study and Treatment of Haematological Malignances)